Brokerages Anticipate Alpine Immune Sciences Inc (ALPN) to Announce -$0.62 EPS

Wall Street brokerages predict that Alpine Immune Sciences Inc (NASDAQ:ALPN) will announce earnings of ($0.62) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Alpine Immune Sciences’ earnings, with estimates ranging from ($0.66) to ($0.57). Alpine Immune Sciences reported earnings per share of ($0.57) during the same quarter last year, which would suggest a negative year over year growth rate of 8.8%. The company is expected to announce its next earnings report on Thursday, August 8th.

On average, analysts expect that Alpine Immune Sciences will report full year earnings of ($2.78) per share for the current fiscal year, with EPS estimates ranging from ($3.68) to ($2.35). For the next financial year, analysts forecast that the firm will post earnings of ($2.36) per share, with EPS estimates ranging from ($2.96) to ($1.84). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPN) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.70) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.01).

A number of analysts have commented on the stock. Zacks Investment Research downgraded shares of Alpine Immune Sciences from a “buy” rating to a “hold” rating in a report on Friday. Oppenheimer set a $13.00 price objective on shares of Alpine Immune Sciences and gave the company a “buy” rating in a report on Tuesday, March 19th. ValuEngine upgraded shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, March 5th. Finally, reiterated a “buy” rating and issued a $13.00 price objective on shares of Alpine Immune Sciences in a report on Tuesday, February 12th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $12.07.

ALPN stock traded down $0.16 during mid-day trading on Tuesday, reaching $6.08. The company’s stock had a trading volume of 683 shares, compared to its average volume of 10,078. The company has a market cap of $84.14 million, a price-to-earnings ratio of -2.31 and a beta of 2.06. The company has a current ratio of 6.59, a quick ratio of 6.59 and a debt-to-equity ratio of 0.05. Alpine Immune Sciences has a fifty-two week low of $3.66 and a fifty-two week high of $10.57.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its holdings in shares of Alpine Immune Sciences by 9.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 41,667 shares of the biotechnology company’s stock worth $286,000 after buying an additional 3,578 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Alpine Immune Sciences by 5.2% during the 3rd quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after buying an additional 11,200 shares during the last quarter. Vanguard Group Inc increased its holdings in shares of Alpine Immune Sciences by 5.2% during the 3rd quarter. Vanguard Group Inc now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after buying an additional 11,200 shares during the last quarter. Raymond James & Associates acquired a new stake in shares of Alpine Immune Sciences during the 1st quarter worth approximately $94,000. Finally, Victory Capital Management Inc. increased its holdings in shares of Alpine Immune Sciences by 109.0% during the 4th quarter. Victory Capital Management Inc. now owns 136,072 shares of the biotechnology company’s stock worth $501,000 after buying an additional 70,980 shares during the last quarter. Institutional investors and hedge funds own 53.79% of the company’s stock.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.

Further Reading: What are the qualifications of a portfolio manager?

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.